In vivo gene therapies have reportedly made significant progress, with some outlets suggesting 2025 as a breakthrough year for the field. There have been developments in clinical trials, including the completion of enrollment in a phase 3 study for a treatment for hereditary angioedema. Additionally, there have been advancements in gene editing technologies, including the use of CRISPR for personalized therapy, although the overall impact and potential of these developments are still being assessed.